Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Otitis Externa
Interventions
Ciprofloxacin/Dexamethasone, Ciprodex (R), Placebo
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
27
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 23 more
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cholera Anti-Secretory Treatment Trial

NCT04150250
Conditions
Cholera
Interventions
iOWH032, Placebo, V. cholerae Challenge, Antibiotics
Drug · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 44 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Dose Ranging Study of OTO-201 in AOMT

NCT02719158
Conditions
Acute Otitis Media, AOMT
Interventions
6 mg ciprofloxacin, 12 mg ciprofloxacin, Sham
Drug · Other
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Recruiting Not applicable Interventional Accepts healthy volunteers

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

NCT05286931
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Ciprofloxacin 500 mg
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions
Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida
Conditions
Colorectal Cancer, CRC
Interventions
Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Richmond, Virginia
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Formulation on Ciprofloxacin Oral Absorption

NCT00992329
Conditions
Healthy
Interventions
ciprofloxacin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Recurrent Uti
Interventions
Saccharomyces Boulardii 250 MG [Florastor]
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pulp Necrosis
Interventions
Double Antibiotic Paste, Triple Antibiotic Paste, Mineral Trioxide Aggregate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
7 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Uncomplicated Bacterial Cystitis
Interventions
Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days, ciprofloxacin 250 mg BID x 3 days
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Conditions
Otitis Media in Patients With Tympanostomy Tubes
Interventions
Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
6 Months to 12 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more
Conditions
Bladder Cancer
Interventions
cephalexin, surgical procedure, Ciprofloxacin
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
90
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Completed Phase 4 Interventional Results available

Optimal Care of Complicated Appendicitis

NCT03159754
Conditions
Appendicitis, Perforated Appendicitis, Ruptured Appendicitis, Complicated Appendicitis
Interventions
Early Appendectomy, Interval Appendectomy, Antibiotics
Procedure · Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

NCT01659866
Conditions
Infection
Interventions
Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
563 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Results available

Phase 3 Study of OTO-201 in Acute Otitis Externa

NCT02801370
Conditions
Acute Otitis Externa, Swimmer's Ear
Interventions
12 mg ciprofloxacin, Sham Control
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Conditions
Tooth, Nonvital
Interventions
Regenerative Endodontic Procedure (REP)
Other
Lead sponsor
Boston University
Other
Eligibility
7 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Otorrhea, Otitis Media With Effusion in Children
Interventions
Otiprio, Ciprodex
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tissue Characterization in Teeth Treated With a Regeneration Protocol

NCT00881907
Conditions
Pulp Necrosis
Interventions
Triple Antibiotic Paste
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
10 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio